[A18-67] Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V
|2019-01-15||Extract of dossier assessment||144 kB|
|2019-01-15||Dossier assessment (German version)||822 kB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Extract of dossier assessment
Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.